Leerink Partnrs Has Negative Outlook for TMO FY2025 Earnings

Key Points

• Leerink Partners has lowered its FY2025 earnings per share estimate for Thermo Fisher Scientific to $22.47, down from $22.53, while the consensus estimate remains higher at $23.28 per share.
• Research analysts have mixed views on Thermo Fisher, with price targets ranging from $510.00 to $650.00, and a majority rating the stock as a "Moderate Buy."
• Despite worries about earnings, Thermo Fisher Scientific's shares experienced a slight gain of 0.3%, opening at $527.34, supported by a solid quarterly revenue of $10.86 billion, exceeding expectations.

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2025 EPS estimates for shares of Thermo Fisher Scientific in a research note issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $22.47 per share for the year, down from their previous estimate of $22.53. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific's Q1 2026 earnings at $5.63 EPS and FY2026 earnings at $24.57 EPS.

Several other research analysts also recently issued reports on the stock. Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Barclays upped their target price on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an "overweight" rating in a research report on Thursday, October 2nd. JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research report on Thursday, October 9th. Finally, HSBC restated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $589.10.

Thermo Fisher Scientific Stock Up 0.3%

Shares of NYSE TMO opened at $527.34 on Thursday. The firm's 50-day simple moving average is $492.55 and its 200 day simple moving average is $448.75. The company has a market cap of $199.13 billion, a price-to-earnings ratio of 30.50, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS.

Institutional Trading of Thermo Fisher Scientific

A number of large investors have recently bought and sold shares of the business. Elevation Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 35.1% during the 3rd quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company's stock worth $37,000 after purchasing an additional 20 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares in the last quarter. S.A. Mason LLC increased its stake in Thermo Fisher Scientific by 7.0% during the 3rd quarter. S.A. Mason LLC now owns 319 shares of the medical research company's stock worth $155,000 after purchasing an additional 21 shares in the last quarter. Lafayette Investments Inc. increased its stake in Thermo Fisher Scientific by 2.4% during the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company's stock worth $376,000 after purchasing an additional 22 shares in the last quarter. Finally, Diversified Enterprises LLC increased its stake in Thermo Fisher Scientific by 1.6% during the 3rd quarter. Diversified Enterprises LLC now owns 1,411 shares of the medical research company's stock worth $684,000 after purchasing an additional 22 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 in the last ninety days. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.